'He was like a zombie': off-label prescription of antipsychotic drugs in dementia

Rosie Harding*, Elizabeth Peel

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

This paper explores the legal position of the off-label prescription of antipsychotic medications to people with dementia who experience behavioural and psychological symptoms of dementia (BPSD). Dementia is a challenging illness, and BPSD can be very difficult for carers to manage, with evidence that this contributes to carer strain and can result in the early institutionalisation of people with dementia. As a result, the prescription of antipsychotic and other neuroleptic medications to treat BPSD has become commonplace, in spite of these drugs being untested and unlicensed for use to treat older people with dementia. In recent years, it has become apparent through clinical trials that antipsychotic drugs increase the risk of cerebrovascular accident (stroke) and death in people with dementia. In addition, these types of medication also have other risk factors for people with dementia, including over-sedation and worsening of cognitive function. Drawing on recent questionnaire (n = 185), focus group (n = 15), and interview (n = 11) data with carers of people with dementia, this paper explores the law relating to off-label prescription, and the applicability of medical negligence law to cases where adverse events follow the use of antipsychotic medication. It is argued that the practice of off-label prescribing requires regulatory intervention in order to protect vulnerable patients.

Original languageEnglish
Pages (from-to)243-277
Number of pages35
JournalMedical Law Review
Volume21
Issue number2
Early online date9 Oct 2012
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Prescription Drugs
dementia
Antipsychotic Agents
Dementia
medication
drug
Behavioral Symptoms
Caregivers
Prescriptions
Psychology
Stroke
legal position
Off-Label Use
Institutionalization
Law
Malpractice
stroke
Focus Groups
institutionalization
Cognition

Keywords

  • Alzheimer's disease
  • antipsychotics
  • dementia
  • medical negligence
  • off-label
  • tort

Cite this

Harding, Rosie ; Peel, Elizabeth. / 'He was like a zombie' : off-label prescription of antipsychotic drugs in dementia. In: Medical Law Review. 2013 ; Vol. 21, No. 2. pp. 243-277.
@article{e421beb02b5542ab8542f8174223f85f,
title = "'He was like a zombie': off-label prescription of antipsychotic drugs in dementia",
abstract = "This paper explores the legal position of the off-label prescription of antipsychotic medications to people with dementia who experience behavioural and psychological symptoms of dementia (BPSD). Dementia is a challenging illness, and BPSD can be very difficult for carers to manage, with evidence that this contributes to carer strain and can result in the early institutionalisation of people with dementia. As a result, the prescription of antipsychotic and other neuroleptic medications to treat BPSD has become commonplace, in spite of these drugs being untested and unlicensed for use to treat older people with dementia. In recent years, it has become apparent through clinical trials that antipsychotic drugs increase the risk of cerebrovascular accident (stroke) and death in people with dementia. In addition, these types of medication also have other risk factors for people with dementia, including over-sedation and worsening of cognitive function. Drawing on recent questionnaire (n = 185), focus group (n = 15), and interview (n = 11) data with carers of people with dementia, this paper explores the law relating to off-label prescription, and the applicability of medical negligence law to cases where adverse events follow the use of antipsychotic medication. It is argued that the practice of off-label prescribing requires regulatory intervention in order to protect vulnerable patients.",
keywords = "Alzheimer's disease, antipsychotics, dementia, medical negligence, off-label, tort",
author = "Rosie Harding and Elizabeth Peel",
year = "2013",
month = "6",
doi = "10.1093/medlaw/fws029",
language = "English",
volume = "21",
pages = "243--277",
journal = "Medical Law Review",
issn = "0967-0742",
publisher = "Oxford University Press",
number = "2",

}

'He was like a zombie' : off-label prescription of antipsychotic drugs in dementia. / Harding, Rosie; Peel, Elizabeth.

In: Medical Law Review, Vol. 21, No. 2, 06.2013, p. 243-277.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 'He was like a zombie'

T2 - off-label prescription of antipsychotic drugs in dementia

AU - Harding, Rosie

AU - Peel, Elizabeth

PY - 2013/6

Y1 - 2013/6

N2 - This paper explores the legal position of the off-label prescription of antipsychotic medications to people with dementia who experience behavioural and psychological symptoms of dementia (BPSD). Dementia is a challenging illness, and BPSD can be very difficult for carers to manage, with evidence that this contributes to carer strain and can result in the early institutionalisation of people with dementia. As a result, the prescription of antipsychotic and other neuroleptic medications to treat BPSD has become commonplace, in spite of these drugs being untested and unlicensed for use to treat older people with dementia. In recent years, it has become apparent through clinical trials that antipsychotic drugs increase the risk of cerebrovascular accident (stroke) and death in people with dementia. In addition, these types of medication also have other risk factors for people with dementia, including over-sedation and worsening of cognitive function. Drawing on recent questionnaire (n = 185), focus group (n = 15), and interview (n = 11) data with carers of people with dementia, this paper explores the law relating to off-label prescription, and the applicability of medical negligence law to cases where adverse events follow the use of antipsychotic medication. It is argued that the practice of off-label prescribing requires regulatory intervention in order to protect vulnerable patients.

AB - This paper explores the legal position of the off-label prescription of antipsychotic medications to people with dementia who experience behavioural and psychological symptoms of dementia (BPSD). Dementia is a challenging illness, and BPSD can be very difficult for carers to manage, with evidence that this contributes to carer strain and can result in the early institutionalisation of people with dementia. As a result, the prescription of antipsychotic and other neuroleptic medications to treat BPSD has become commonplace, in spite of these drugs being untested and unlicensed for use to treat older people with dementia. In recent years, it has become apparent through clinical trials that antipsychotic drugs increase the risk of cerebrovascular accident (stroke) and death in people with dementia. In addition, these types of medication also have other risk factors for people with dementia, including over-sedation and worsening of cognitive function. Drawing on recent questionnaire (n = 185), focus group (n = 15), and interview (n = 11) data with carers of people with dementia, this paper explores the law relating to off-label prescription, and the applicability of medical negligence law to cases where adverse events follow the use of antipsychotic medication. It is argued that the practice of off-label prescribing requires regulatory intervention in order to protect vulnerable patients.

KW - Alzheimer's disease

KW - antipsychotics

KW - dementia

KW - medical negligence

KW - off-label

KW - tort

UR - http://www.scopus.com/inward/record.url?scp=84877935174&partnerID=8YFLogxK

UR - http://medlaw.oxfordjournals.org/content/21/2/243

U2 - 10.1093/medlaw/fws029

DO - 10.1093/medlaw/fws029

M3 - Article

C2 - 23047844

AN - SCOPUS:84877935174

VL - 21

SP - 243

EP - 277

JO - Medical Law Review

JF - Medical Law Review

SN - 0967-0742

IS - 2

ER -